ELIMINATE trial now open in NZ
The Eliminate trial will investigate whether combining two breast cancer treatments before surgery is more effective than one treatment alone for women with large and complex ER+ breast cancer.
Breast cancer is often treated by giving surgery first which may be followed by additional (adjuvant) treatment. However, sometimes, if the breast cancer is large or complex neo-adjuvant therapy (treatment before surgery) may be given, and this is typically chemotherapy. This trial aims to find out if combining chemotherapy with a hormone therapy (an aromatase inhibitor) can shrink the breast cancer before surgery. If so, the need for more extensive surgery such as mastectomy and reconstruction could potentially be avoided.
Approximately 80% of all breast cancers are ER+ (Estrogen-receptor positive) which means the breast cancer cells grow in response to the hormone estrogen. In this trial, patients will be given an aromatase inhibitor called Letrozole which blocks the aromatase enzyme that is responsible for producing estrogen. This is an effective hormone treatment for postmenopausal women.
It is hoped results of the study will determine the effectiveness of giving the two treatments (Letrozole and chemotherapy) in combination and thus improve treatment choices and outcomes for women with ER+ breast cancer.
The trial aims to recruit 123 patients across Australia and New Zealand. In New Zealand, the trial recently opened in the Waikato and is expected to open in the coming months in Auckland, Palmerston North and Christchurch.
The trial is open to women with ER+, HER2- invasive breast cancer. If you are interested in joining the trial speak to your breast surgeon who will be able to determine your eligibility. Patients are advised not to contact centres directly. If your surgeon is not aware of the trial, patients are encouraged to contact their local medical oncologist.
For further information regarding the Eliminate Study, please visit - https://www.bcia.org.au/clinical-trials/anz1401/eliminate
4th September, 2015